Story · Medicine & Biotech

J2H Biotech's MASH drug reduces liver fat in phase 2a trial

1 outlet · first reported by Korea Biomedical Review on

J2H Biotech said Tuesday that its experimental MASH treatment, J2H-1702, significantly reduced liver fat compared with placebo in a phase 2a trial, according to results presented at The Liver Meeting 2026 in Denver, Colorado.Professor Jun Dae-won of Hanyang University College of Medicine presented t (Korea Biomedical Review)

Coverage, in order

  1. Korea Biomedical Review South Korea obscure study
    J2H Biotech's MASH drug reduces liver fat in phase 2a trial

    J2H Biotech said Tuesday that its experimental MASH treatment, J2H-1702, significantly reduced liver fat compared with placebo in a phase 2a trial, according to results presented at The Liver Meeting 2026 in Denver, Colorado.Professor Jun Dae-won of Hanyang University College of Medicine presented t

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.